Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST Control in Apparent Resistant Arterial Hypertension
NCT07259733Recruiting
- Sponsor
- Instituto Dante Pazzanese de Cardiologia
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of perindopril, indapamide and amlodipine in resistant hypertension (RH) (2 arms), sponsored by Instituto Dante Pazzanese de Cardiologia. Primary endpoint: Rate of 24-hour Blood Pressure Control Measured by ABPM at 12 weeks. Started Jul 2023; status: recruiting.
02
Drugs
perindoprilindapamideamlodipine
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT07259733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259733.